
药物研发新靶点——脂激酶介绍之磷脂酰肌醇激酶 - 知乎
脂质激酶目前有两大家族, 磷脂酰肌醇激酶 (phosphatidylinositol kinase; PI kinase)和 甘油二脂激酶 (Diacyl Glycerol Kinase,DGK)。 今天我们重点介绍下 磷脂酰肌醇-激酶。 图片来源于网络. 磷脂酰肌醇(Phosphatidylinositol,PI),及其衍生物是组成细胞膜和细胞器膜的重要成分,是保持膜正常流动性和功能的必不可少的组成部分。 它由两个部分组成(如图一)肌醇头部(上面),和二酰甘油尾部(下面),这也是所有磷酸肌醇的主要骨架。 这两个部分也是未来形成 …
DGKA Gene - GeneCards | DGKA Protein | DGKA Antibody
2024年12月24日 · DGKA (Diacylglycerol Kinase Alpha) is a Protein Coding gene. Diseases associated with DGKA include Fibrosclerosis Of Breast and Lymphoproliferative Syndrome, X-Linked, 1. Among its related pathways are GPCR downstream signalling and Response to elevated platelet cytosolic Ca2+.
DGKA Mediates Resistance to PD-1 Blockade - PubMed
Pharmacologic ablation of Dgka postponed T-cell exhaustion and delayed development of resistance to PD-1 blockade. Dgka inhibition also enhanced the efficacy of anti-PD-1 therapy. We further found that the expression of DGKA in cancer cells promoted tumor growth via the AKT signaling pathway, suggesting that DGKA might be a target in tumor ...
DGKA - Wikipedia
Diacylglycerol kinase alpha is an enzyme that in humans is encoded by the DGKA gene. [5] [6] [7] The protein encoded by this gene belongs to the eukaryotic diacylglycerol kinase family. It acts as a modulator that competes with protein kinase C for the second messenger diacylglycerol in intracellular signaling pathways.
CIR封面文章|一石二鸟!周鹏辉团队发现DGKA在肿瘤免疫治疗中 …
2021年4月7日 · 通过小分子抑制剂阻断DGKA,既可激活T细胞的抗肿瘤免疫反应,又可抑制肿瘤本身的生长,起到“一石二鸟”的治疗功效。 将DGKA抑制剂与PD-1抗体联用,具有显著的协同效应,是一种非常理想的联合方案。 中山大学肿瘤防治中心付凌怡博士为本文第一作者,周鹏辉教授为本文通讯作者。 周鹏辉教授课题组长期从事“肿瘤免疫学和肿瘤免疫治疗”研究。 主要通过研究免疫系统和肿瘤之间的相互作用,鉴定肿瘤特异的免疫细胞,尤其是识别肿瘤抗原的T细胞,以及 …
AACR大会直击|靶向DGKA的免疫肿瘤疗法,新颖DGKA抑制剂IS…
临床前候选化合物ISM4312A是一款潜在全球首创(first-in-class)的DGKA小分子抑制剂,在癌症免疫治疗中显示了出色的药效和选择性。 ISM4312A在体外可增强T细胞活性,体内实验表明,无论单药使用还是与PD-1抗体联用,ISM4312A均展现出较强的抗肿瘤效果。
二酰甘油激酶α(DGKA)基因 | MCE - MCE-生物活性分子大师
该基因编码的蛋白质属于真核二酰基甘油激酶家族。 它充当调节剂,与蛋白激酶 C 竞争细胞内信号通路中的第二信使甘油二酯。 它还在磷脂酰肌醇的再合成和将二酰基甘油磷酸化为磷脂酸方面发挥重要作用。 已经为该基因鉴定了几种编码不同同种型的转录物变体。 [RefSeq 提供,2017 年 4 月] The protein encoded by this gene belongs to the eukaryotic diacylglycerol kinase family.
一个分子,双重突破:AI制药再获验证,英矽智能提出肿瘤免疫耐 …
据悉,临床前候选化合物ISM4312A是一款潜在全球首创(first-in-class)的DGKA小分子抑制剂,在癌症免疫治疗中显示了出色的药效和选择性。 ISM4312A在体外可增强T细胞活性,体内实验表明,无论单药使用还是与PD-1抗体联用,ISM4312A均展现出较强的抗肿瘤效果。
DGKA Mediates Resistance to PD-1 Blockade
2021年4月1日 · Here, we demonstrated that diacylglycerol kinase alpha (Dgka) mediated T-cell dysfunction during anti–PD-1 therapy by exacerbating the exhaustion of reinvigorated tumor-specific T cells. Pharmacologic ablation of Dgka postponed T-cell exhaustion and delayed development of resistance to PD-1 blockade.
Therapeutic Targeting of DGKA-Mediated Macropinocytosis Leads …
2021年4月15日 · Ritanserin, an inhibitor of diacylglycerol kinase alpha (DGKA), was identified as a selective inhibitor of proliferation of Tsc2-/-mouse embryonic fibroblasts (MEF), with no impact on Tsc2 +/+ MEFs. DGKA is a lipid kinase that metabolizes diacylglycerol to phosphatidic acid, a key component of plasma membranes.